No headlines found.
Newsfile (Mon, 13-Jan 8:00 AM ET)
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Newsfile (Thu, 19-Dec 7:30 AM ET)
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Newsfile (Mon, 2-Dec 4:00 PM ET)
Adaptimmune Reports Q3 2024 Financial and Business Updates
Newsfile (Wed, 13-Nov 4:05 PM ET)
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
Newsfile (Wed, 13-Nov 9:00 AM ET)
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Newsfile (Tue, 5-Nov 9:20 AM ET)
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
Newsfile (Thu, 31-Oct 5:20 PM ET)
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Adaptimmune Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol ADAP.
As of January 29, 2025, ADAP stock price declined to $0.58 with 312,900 million shares trading.
ADAP has a beta of 2.91, meaning it tends to be more sensitive to market movements. ADAP has a correlation of 0.17 to the broad based SPY ETF.
ADAP has a market cap of $149.05 million. This is considered a Micro Cap stock.
Last quarter Adaptimmune Therapeutics PLC - American Depositary Shares reported $41 million in Revenue and -$.07 earnings per share. This beat revenue expectation by $30 million and exceeded earnings estimates by $.06.
In the last 3 years, ADAP traded as high as $3.32 and as low as $.42.
The top ETF exchange traded funds that ADAP belongs to (by Net Assets): SPDW, FESM, GWX, QQQS.
ADAP has underperformed the market in the last year with a price return of -20.2% while the SPY ETF gained +24.9%. ADAP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.0% and -1.3%, respectively, while the SPY returned +4.0% and +3.4%, respectively.
ADAP support price is $.56 and resistance is $.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADAP shares will trade within this expected range on the day.